Immuron Provides Update on First Half of FY20 Results
March 03, 2020 07:00 ET
|
Immuron Limited
Key Highlights: Strong continued growth of Travelan® sales reported in all marketsGlobal sales reached USD $1.1 million (AUD $1.68 million) for first half FY 2020 up 55% from first half FY 2019North...
Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak
February 03, 2020 07:30 ET
|
Immuron Limited
Key Highlights: Wuhan coronavirus outbreak expanding to global health emergencyOutbreak while viral in nature highlights the role of global travel leading to respiratory and gastrointestinal...
North American Travelan® sales up 98% in the first half of FY20
January 28, 2020 08:30 ET
|
Immuron Limited
Key Highlights: Strong continued growth of Travelan® sales reported in all marketsNorth American Travelan® sales up by 98% YoY in the first half of FY20Immuron achieved 55% YoY growth for the first...
Immuron CEO Dr. Gary S. Jacob to Present at Biotech Showcase Conference on January 13, 2020
January 08, 2020 08:00 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea
November 21, 2019 07:00 ET
|
Immuron Limited
Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD)Phase 3 clinical trial of IMM-124E to prevent TD planned for...
Immuron Receives AUD $0.53M R&D Tax Concession Refund
November 04, 2019 11:30 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron North American Q1 Sales Up 111% YoY
October 14, 2019 07:30 ET
|
Immuron Limited
Key Highlights: First Quarter of FY2020 (Q1) North American sales grew by 111% YoY to $269K AUDQ1 US Travelan® sales increased by +81% YoY to $232K AUDGlobal Immuron sales continued an upward...
New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter
October 02, 2019 09:00 ET
|
Immuron Limited
Key Highlights: AU $5.5 (USD $3.7) million funding approved by the U.S. Department of Defense to develop and clinically evaluate a new oral therapeutic targeting Campylobacter and ETECNaval Medical...
U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea
September 04, 2019 06:00 ET
|
Immuron Limited
Key Highlights: Major goal of study was to evaluate Travelan®’s ability to bind and react to a variety of infectious Vibrio cholera strains from Southeast Asia Pathogenic bacteria evaluated in study...
Immuron to Commence Non-Deal Investor Roadshow
August 16, 2019 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...